The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: Rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)
- Charlotte Höybye
- , Lars Sävendahl
- , Henrik Thybo Christesen
- , Peter Lee
- , Birgitte Tønnes Pedersen
- , Michael Schlumpf
- , John Germak
- , Judith Ross
- Karolinska Institutet
- University of Southern Denmark
- Pennsylvania State University
- Novo Nordisk Foundation
Producción científica › revisión exhaustiva
46
Citas
(Scopus)